Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
about
Oxycodone for neuropathic pain and fibromyalgia in adultsOxycodone for neuropathic pain and fibromyalgia in adultsOxycodone for neuropathic pain in adultsProtocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.Oxycodone DETERx®: A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic PainSafety concerns with long-term opioid use.Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.Opioid formulations with sequestered naltrexone: a perspective review.Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitabilityPharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Nonmedical use of prescription drugs in the European UnionDynamic model of nonmedical opioid use trajectories and potential policy interventions.Buprenorphine Prescribing: To Expand or Not to ExpandPharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneA practical and ethical solution to the opioid scheduling conundrum.The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.Controlling controlled substances abuse and misuse by managed care payers: a new generation of risk management initiatives?Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Abuse-deterrent formulations: part 1 - development of a formulation-based classification system.Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain.Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.The role of abuse-deterrent formulations in countering opioid misuse and abuse.Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.Opioid abuse-deterrent strategies: role of clinicians in acute pain management.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.Oxycodone for pain in fibromyalgia in adults.
P2860
Q24193845-A66F0C7B-908A-418A-896A-407F14969C08Q24200889-727B71F3-E1CC-46D3-AF33-0A8942565A60Q26470985-E574A079-648A-48AD-BCE9-B72C0A7C0B2BQ27318074-C4E98216-C550-40F0-BD42-E5CFD817AD8EQ28071792-C23DC538-1754-4BDE-AEFF-25DBD62089E2Q30251602-36C8077E-2828-4D2F-B22A-827814B2B939Q30677208-70A49E23-0371-4D14-B1AF-D85263722525Q33633386-D09D6DDD-D08B-487C-BF93-B873EC43414AQ33685208-6EE829AB-5F53-4862-830E-486953A8D52AQ33949447-403E88C6-E3A8-4BF5-A940-61F365D17F13Q34808676-2D54BFF2-10CE-41D3-885A-7AE247F67011Q35209803-FEAA05DF-6E2E-411F-857B-B679F9FFBEA4Q35252121-1A90C4A0-69B3-481F-85D3-EA3DD67E19B5Q35278475-7F1F0CC4-E00E-46F0-89BF-CCEFDA03AB66Q36094236-160C401D-B673-405F-862C-C01BCCF6BC0CQ36389066-1D95EB66-411A-45F1-A124-96E53C3A9843Q36855631-DA88B925-1237-4D84-980A-719632F96B5CQ36878225-DC462A74-CD04-42C7-BE7E-CE6459059971Q36972164-E5C4A05A-F09D-441F-B2BA-491237D52F87Q37390980-DA8A219E-9675-47D6-9684-A528CE8E71BDQ37404465-C1784DE1-0863-4F3F-93CB-4A6A7DCCB8E9Q37616572-C2A55F35-D455-433C-8D87-B8D9A8F01002Q37616576-CD5BEFDA-A99F-4B8C-8152-617EC69C596FQ38160935-4F88291B-C94B-4BC8-8F2C-52FD30FCBA61Q38181019-AF69371D-6D2A-4661-903A-6E803C2EDC74Q38186618-8DBC0B31-7567-42C5-8336-8F9F398A254FQ38241632-0E487A13-1CF0-4626-A4EF-5C5C9936D436Q38265486-874B7BE4-638A-465F-8B84-76F7A3077445Q38271152-2742EAE1-FF85-49C2-A8F8-CCDC07D09F85Q38356233-BAEAB0AD-66EA-4370-A3DE-E36FD63B4AA6Q38611937-B5EF5A98-1E14-4675-9850-BD933AE49523Q38632934-062507AC-2B1D-45BD-88EB-B50782583693Q38643510-ACD69570-56A9-4A5B-B74F-73B36F9E453DQ38644058-A054E8F5-D702-4325-A1AE-0EC0F78F6DB2Q38657470-E60677DA-C7F2-4B45-8F32-B9EF2E68CAD6Q38683620-E06ED7B9-59EA-4A2A-A58A-DD9FEAF51CCAQ38707436-D48A8944-7EE5-4889-83FE-9EB3BEDC5F21Q38799636-3877BB73-EA3F-455C-B9C8-02568D6F60A2Q38851461-B2B3FF90-052E-4F8A-9C7D-EDA349EB9972Q38943074-53D9C5E5-276A-4981-B1DA-83C799B48D32
P2860
Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Abuse rates and routes of admi ...... for substance abuse treatment.
@en
Abuse rates and routes of admi ...... for substance abuse treatment.
@nl
type
label
Abuse rates and routes of admi ...... for substance abuse treatment.
@en
Abuse rates and routes of admi ...... for substance abuse treatment.
@nl
prefLabel
Abuse rates and routes of admi ...... for substance abuse treatment.
@en
Abuse rates and routes of admi ...... for substance abuse treatment.
@nl
P2093
P1433
P1476
Abuse rates and routes of admi ...... for substance abuse treatment.
@en
P2093
Craig Landau
Howard Chilcoat
Ryan A Black
Simon H Budman
Theresa A Cassidy
P304
P356
10.1016/J.JPAIN.2012.08.008
P577
2012-11-03T00:00:00Z